What happens after the therapeutic payload has been released?

What is ENDOLEASE?
ENDOLEASE is the first implantable intra-arterial drug delivery platform designed for precision therapy at the site of disease. It enables controlled, localized release of therapeutics directly into the arterial blood flow supplying a defined target tissue, with the goal of improving efficacy while reducing systemic exposure.
How does ENDOLEASE work?
ENDOLEASE is delivered minimally invasively via catheter into a target artery. Once in place, the implant releases therapeutic agents in a controlled and sustained manner into the arterial bloodstream, allowing them to be carried downstream into the capillary network of the intended tissue territory.
Why does localized intra-arterial drug delivery matter?
Many potent therapies are limited by a fundamental challenge: systemic administration distributes drugs throughout the body rather than concentrating them where they are most needed. ENDOLEASE is designed to address this problem by enabling site-directed delivery through the arterial supply of the target tissue, with the potential to improve local drug availability while reducing off-target toxicity.
How is ENDOLEASE different from a drug-eluting stent?
ENDOLEASE is fundamentally different from a drug-eluting stent. Drug-eluting stents are primarily mechanical devices that maintain vessel patency while releasing relatively small amounts of drug into the vessel wall. ENDOLEASE, by contrast, is a dedicated therapeutic delivery platform designed to deliver drugs beyond the vessel wall and into the downstream target tissue.
What types of therapeutics can ENDOLEASE deliver?
ENDOLEASE is being developed as a versatile platform capable of supporting multiple therapeutic classes, including small molecules, biologics such as monoclonal antibodies, and potentially combination therapies. This flexibility allows the platform to be tailored to different disease settings and therapeutic strategies.
Which medical fields could benefit from ENDOLEASE?
ENDOLEASE has broad platform potential wherever localized, high-precision intra-arterial therapy may offer an advantage over systemic treatment. Current focus areas include cardiology, oncology, and neurology, with potential future expansion into additional indications requiring regional, site-specific therapy.
What happens after the therapeutic payload has been released?
After completing its intended release phase, the implant is designed to biodegrade. This supports a transient treatment concept without the need for permanent implantation and reflects the platform’s broader aim of combining therapeutic precision with procedural minimalism.

Why is ENDOLEASE a platform technology?
ENDOLEASE is not being developed as a single-product solution for one disease alone. Its core value lies in a transferable therapeutic principle that can potentially be adapted to different drugs, target tissues, and clinical indications. This platform character creates both broad clinical potential and significant strategic value.
What is the intellectual property status?
ENDOLEASE is backed by a strong international intellectual property strategy. The platform holds global patent priority, with ongoing international filings designed to protect both the core technology and its unique principle of implantable intra-arterial therapeutic delivery.
Who could be a partner for ENDOLEASE?
Potential partners include biotechnology companies, pharmaceutical companies, medical device manufacturers, strategic investors, and academic or clinical collaborators. Such partnerships can accelerate validation, indication-specific development, regulatory advancement, scale-up, and commercialization.
How can partners or investors get involved?
We welcome engagement with partners and investors who share our ambition to advance the next generation of precision drug delivery. Collaboration opportunities may include strategic partnerships, co-development programs, translational validation initiatives, indication-specific programs, manufacturing partnerships, and investment to accelerate clinical and commercial progress.
What stage is ENDOLEASE currently at?
ENDOLEASE is currently in preclinical development. The platform has already generated promising proof-of-concept results and is advancing through a focused translational pathway that includes prototype optimization, preclinical validation, and preparation for future clinical development.